Ertapenem versus Ceftriaxone and Metronidazole As Treatment For Complicated Intra-abdominal Infections

Completed

• Conditions: Complicated intra-abdominal infections; Infections and Infestations; Other and unspecified infectious diseases

• Registration Number: ISRCTN59616541
• Lead Sponsor: Merck and Co., Inc. (USA)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-01-19
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

Current information as of 13/08/09:
1. Male or female patients aged 18 or over
2. Patient has a diagnosis of intra-abdominal infection requiring surgery as evidenced by fever, elevated while blood cell count and abdominal pain

Initial information at time of registration:
Adult patients with intra-abdominal infections requiring surgery

Exclusion Criteria

Added 13/08/09:
1. Patient has another infection, other than abdominal
2. Female patient is pregnant or planning to become pregnant

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Added 13/08/09:<br>Efficacy as measured by clinical response rate in clinically and microbiologically evaluable participants at the test-of-cure (TOC) visit 2 weeks after discontinuation of therapy

Secondary Outcome Measures

Name	Time	Method
Added 13/08/09:<br>Efficacy measured at TOC visit 4 weeks after discontinuation of therapy